Research and Development Expenses Breakdown: Novartis AG vs BioMarin Pharmaceutical Inc.

R&D Spending: Novartis vs BioMarin - A Decade of Innovation

__timestampBioMarin Pharmaceutical Inc.Novartis AG
Wednesday, January 1, 20144615430009086000000
Thursday, January 1, 20156348060008935000000
Friday, January 1, 20166619050009039000000
Sunday, January 1, 20176107530008972000000
Monday, January 1, 20186963280009074000000
Tuesday, January 1, 20197150070009402000000
Wednesday, January 1, 20206281160008980000000
Friday, January 1, 20216287930009540000000
Saturday, January 1, 20226496060009996000000
Sunday, January 1, 202374677300011371000000
Monday, January 1, 202474718400010022000000
Loading chart...

In pursuit of knowledge

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Novartis AG and BioMarin Pharmaceutical Inc. have demonstrated contrasting yet significant commitments to R&D. Novartis, a global healthcare giant, consistently allocated around 9% of its revenue to R&D, peaking in 2023 with a 13% increase from 2014. Meanwhile, BioMarin, a leader in rare disease therapies, showed a steady rise in R&D investment, culminating in a 62% increase over the same period. This trend underscores the industry's relentless pursuit of groundbreaking treatments and therapies. As we look to the future, these investments are poised to drive the next wave of medical breakthroughs, offering hope to millions worldwide.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025